ReviewJournal of translational medicine2026
Agentic systems in computational pathology: architectures, evidence, and translational challenges.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDigital pathology supports whole-slide imaging, remote review, and computational analysis. Most pathology AI systems, however, remain restricted to predefined tasks. Agentic architectures coordinate perception models, language-based reasoning, external tools, and feedback-dependent actions, but their clinical evidence is derived mainly from retrospective benchmarks and research prototypes. MAIN BODY: We review agentic systems in computational pathology using an operational taxonomy based on dynamic control flow, inference-time tool selection, and knowledge integration. We assess architectures, enabling technologies, and applications in diagnosis, prognosis, and therapeutic support. Reported gains are difficult to attribute to agentic organization because studies differ in backbones, training data, and inference budgets. We therefore emphasize validation scope, computational cost, workflow integration, hallucination and security risks, regulatory requirements, patient preferences, and the conditions under which specialist non-agentic models remain preferable.
conclusionsAgentic architectures have established technical feasibility, but not clinical benefit. Translation should prioritize verifiable tasks, matched comparisons, prospective and external validation, lifecycle governance, and interfaces that preserve pathologist oversight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.